Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...

Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains ...

Plus, salon owners are seeing a massive drawdown in clients coming in for their regular scheduled appointments, citing ...

Less expensive versions of popular weight-loss medications like Wegovy and Zepbound are soon going to be taken off the market ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.